NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

NCT03240861
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ESO, HLA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult, Senior)
Location of Metastases: 
Additional Notes: Tumors must be HLA-A*0201 positive & NY-ESO-1+
Exclusions: Patients with known clinically active brain metastases- see trial for details; Patients with liver metastases, but no other metastatic sites
https://ClinicalTrials.gov/show/NCT03240861

Comments are closed.

Up ↑